VENTANA PD-L1 (SP142) Assay
PD-L1 predictive assay | Guiding immunotherapy
The VENTANA PD-L1 (SP142) Assay identifies patients most likely to benefit from TECENTRIQ®
Health Canada approved.
Using the right test to determine PD-L1 status for immunotherapy options is important. The VENTANA PD-L1 (SP142) Assay* is the first and only Health Canada approved test predictive for TECENTRIQ® in urothelial carcinoma (UC) patients. This novel assay is also the first to evaluate patient’s PD-L1 expression using immune cell staining and scoring within the tumor microenvironment, providing you with information that can guide immunotherapy decisions.
The VENTANA PD-L1 (SP142) Assay:
- Health Canada approved to assess UC patient treatment benefit from to TECENTRIQ®
- Informative for the clinician of a patient’s potential objective response rate (ORR)
- Optimized to enhance visual contrast of immune cell staining within the tumor microenvironment
- Stains PD-L1 in both tumor cells (TC) and tumor-infiltrating immune cells (IC)
*Only available on the VENTANA BenchMark ULTRA Instrument.